Econ Market Research
Home
Press ReleasesBlogsTestimonialsCareerAuthors
ServicesAboutContact
Econ Market Research Report Cover

Extracorporeal Membrane Oxygenation Cannula Market

Extracorporeal Membrane Oxygenation Cannula Market Size, Share, Trends, Growth, and Industry Analysis, By Type, By Patient Type, By Application, By End Use, Regional Analysis and Forecast Period 2026-2035.

Last Updated:
Oct 30, 2026
Base year:
2025
Historical Data:
2022 - 2024
Region:
Global
Pages:
150+
Report Format:
PDF + Excel
Report ID:
EMR002835

Forecast Period

2026 - 2035

CAGR

4.1%

2025 Market Size

US$ 37.18 Million

2026 Market Size

US$ 38.7 Million

2035 Market Size

US$ 55.56 Million

Extracorporeal Membrane Oxygenation Cannula Market Overview

As per Econ Market Research analysis, the Global Extracorporeal Membrane Oxygenation Cannula Market was recorded at US$ 38.7 Million in 2026 and is projected to expand to US$ 55.56 Million by 2035, registering a CAGR of 4.1% over the forecast period. The base year used is 2025.

The global Extracorporeal Membrane Oxygenation Cannula Market supports specialized medical procedures for patients experiencing severe respiratory or cardiac failure. ECMO cannulas establish vascular access between the patient's circulation and an extracorporeal circuit, allowing temporary oxygenation or circulatory support when conventional treatment is insufficient. The Extracorporeal Life Support Organization recorded 154,568 ECMO runs between 2009 and 2022, demonstrating the established clinical role of extracorporeal support. Cannula selection depends on patient anatomy, treatment configuration, required blood flow, and expected support duration. These factors create demand for specialized devices rather than interchangeable vascular catheters.

The United States represents an established market supported by advanced intensive care infrastructure, cardiovascular treatment facilities, and specialized extracorporeal life support programs. Hospitals purchase ECMO cannulas through regulated medical device procurement channels, frequently alongside oxygenators, centrifugal pumps, and associated disposable circuits. The Food and Drug Administration maintains device classifications for single-lumen and dual-lumen ECMO cannulas, with applicable products undergoing premarket evaluation. Clinical institutions emphasize product traceability, manufacturer instructions, and compatibility with existing equipment. Hospital purchasing decisions therefore depend on clinical performance, regulatory clearance, product availability, and institutional treatment protocols.

Extracorporeal Membrane Oxygenation Cannula Market size and forecast chart showing growth from US$ 38.7 Million in 2026 to US$ 55.56 Million by 2035 at a CAGR of 4.1%.
Extracorporeal Membrane Oxygenation Cannula Market size forecast, 2026-2035

The European ECMO cannula industry operates within a medical device regulatory environment shaped by conformity assessment, technical documentation, and post-market surveillance requirements. Specialized cardiothoracic centers in Germany, France, Italy, and other European countries support clinical adoption through established intensive care and perfusion services. European manufacturers and suppliers provide arterial, venous, and dual-lumen cannulation solutions for different extracorporeal applications. Procurement teams assess device certification, sterilization assurance, clinical evidence, and compatibility with hospital equipment. Cross-border medical device distribution also requires manufacturers to maintain effective quality management and authorized market access arrangements.

Dual-lumen cannulation has become an important area of clinical and technological interest, particularly for prolonged veno-venous ECMO support. These devices allow venous drainage and reinfusion through a single vascular access site, potentially simplifying patient positioning and rehabilitation. A clinical study reported out-of-bed mobilization in 25.6% of patients receiving dual-lumen cannulation, supporting investigation of its potential advantages for selected patients. However, successful mobilization also depends on patient stability, secure device positioning, and experienced clinical supervision. Manufacturers consequently emphasize cannula fixation, appropriate flow characteristics, and configurations that support different treatment requirements.

Image-guided cannulation is another relevant trend influencing device selection and clinical workflow. Ultrasound and echocardiographic assessment help clinicians evaluate vascular access and confirm appropriate positioning during complex procedures. Research using computational fluid dynamics is also examining how cannula orientation, drainage geometry, and reinfusion patterns influence recirculation and blood damage. These findings provide engineering insights that may inform future catheter development without automatically establishing clinical superiority.

Hospitals are also giving greater attention to standardized ECMO equipment configurations and digital monitoring of extracorporeal circuits. Connected systems can support the observation of blood flow, circuit pressures, and other operational parameters, although conventional cannulas are generally passive devices rather than independent digital monitoring systems. Procurement preferences increasingly reflect the need for dependable interfaces between disposable vascular access products and extracorporeal support equipment. This approach encourages coordinated product evaluation across clinical engineering, perfusion, critical care, and purchasing departments.

Extracorporeal Membrane Oxygenation Cannula Market Dynamics

The ECMO cannula industry is influenced by specialized clinical demand, equipment regulation, hospital purchasing practices, and the availability of experienced medical personnel. Cannulas form an essential component of extracorporeal support but represent only one part of a broader treatment system. Manufacturers must address clinical performance requirements while maintaining reliable sterilization, packaging, distribution, and product documentation. Hospitals evaluate device suitability through multidisciplinary teams because cannulation decisions affect vascular access, blood flow, and overall treatment management. Consequently, market conditions reflect both the availability of clinically appropriate products and the operational readiness of institutions delivering ECMO.

Drivers of Market Growth

Increasing clinical use of temporary extracorporeal support for severe respiratory and cardiac failure.

Severe acute respiratory distress syndrome and refractory cardiogenic shock are important clinical conditions associated with ECMO treatment. When conventional respiratory or circulatory management cannot provide sufficient support, specialist teams may consider extracorporeal assistance for appropriately selected patients. Each treatment requires vascular access compatible with the selected support configuration, creating a direct clinical requirement for cannulas. Device choice must accommodate anticipated blood flow and anatomical limitations while minimizing avoidable access-related complications.

The development of multidisciplinary ECMO services also supports structured purchasing and product evaluation. Cardiothoracic surgeons, intensivists, perfusionists, and specialist nurses contribute different expertise to these programs. Institutions with established treatment pathways are better positioned to maintain appropriate cannula inventories and organize emergency access to essential disposables. This operational infrastructure strengthens the relationship between clinical program development and specialized device procurement.

Market Restraints

Clinical complexity and vascular access complications limit the broader use of ECMO cannulation.

ECMO cannulation is a specialized invasive procedure that requires appropriate patient selection and experienced medical management. Potential complications include bleeding, thrombosis, vascular injury, infection, and compromised blood flow. These risks require hospitals to maintain rigorous cannulation protocols and continuous clinical assessment throughout treatment. Device performance alone cannot eliminate complications associated with patient condition, anticoagulation, or procedural technique.

Smaller medical institutions may lack the multidisciplinary resources needed to operate comprehensive extracorporeal support programs. Establishing such services requires specialized personnel, emergency response arrangements, and access to appropriate monitoring equipment. These requirements restrict ECMO cannula demand primarily to facilities capable of delivering complex critical care. Manufacturers therefore face a relatively specialized customer base compared with suppliers of routine vascular access devices.

Market Opportunities

Development of coordinated ECMO referral and transport networks creates opportunities for specialized vascular access products.

Regionalized critical care networks can connect hospitals without comprehensive ECMO capabilities to experienced treatment centers. Such arrangements create interest in standardized equipment kits, compatible cannulation products, and reliable logistical support. Manufacturers serving these networks may benefit from offering clear product configurations and dependable distribution arrangements. Portable extracorporeal support systems also create additional considerations for secure connections and device management during patient transfer.

Training partnerships represent another potential commercial opportunity. Hospitals establishing referral pathways need education covering device selection, handling, documentation, and compatibility with approved treatment systems. Manufacturers can support institutional readiness through product-specific education and technical information without replacing independent clinical training. Effective coordination between suppliers and specialist centers can improve equipment availability where appropriate ECMO services already exist.

Market Challenges

Maintaining consistent manufacturing quality and uninterrupted availability of sterile ECMO cannulas.

ECMO cannulas require controlled manufacturing processes because defects can compromise a device's intended performance in critical clinical situations. Producers must manage material specifications, dimensional consistency, packaging integrity, and sterilization validation. Supply interruptions are particularly challenging because hospitals may require specific cannula configurations that cannot be substituted without clinical reassessment. Inventory planning must therefore consider product variations, expiration dates, and validated storage conditions.

Manufacturers operating internationally also face different documentation and conformity requirements across regulatory jurisdictions. Product changes may require additional testing, technical assessment, or regulatory submissions before commercial implementation. These obligations affect production planning and the introduction of modified designs. Effective quality systems and supplier oversight remain important for maintaining dependable access to approved devices.

Extracorporeal Membrane Oxygenation Cannula Market SWOT Analysis

Strengths

  • Essential Clinical Function: ECMO cannulas provide the vascular connection required for extracorporeal circulatory access. Their function is fundamental to delivering the prescribed treatment configuration.

  • Specialized Product Design: Dedicated arterial, venous, and dual-lumen designs allow clinicians to select devices suited to different anatomical and treatment requirements.

  • Established Clinical Knowledge: International ECMO practice frameworks provide a foundation for device evaluation, professional education, and consistent institutional procedures.

  • Integrated Equipment Compatibility: Cannulas can be evaluated within established extracorporeal support systems, allowing hospitals to align vascular access products with approved equipment configurations.

Weaknesses

  • Narrow Customer Base: Commercial demand is concentrated among institutions with the facilities and personnel required to provide advanced extracorporeal support.

  • Limited Product Interchangeability: Differences in access configuration, dimensions, and intended use can prevent direct substitution between cannula models.

  • Specialized Procurement Requirements: Product evaluation often involves multiple clinical departments, creating a complex institutional purchasing process.

  • Dependence on Clinical Expertise: The practical usefulness of advanced cannula designs depends partly on appropriate insertion, positioning, and device management.

Opportunities

  • Dedicated Pediatric Engineering: Development of anatomical configurations for smaller patients can address specialized requirements within congenital and pediatric critical care.

  • Improved Packaging Solutions: Better sterile barrier design and transport protection can support reliable inventory management and reduce packaging-related disruption.

  • Expanded Technical Education: Manufacturer-supported device familiarization can help clinical institutions understand product-specific operating limitations and handling requirements.

  • Interdisciplinary Product Testing: Collaboration between biomedical engineers and clinical specialists can improve the relevance of design validation and usability assessments.

Threats

  • Regulatory Noncompliance: Failure to maintain applicable certification or technical documentation can restrict access to important medical device markets.

  • Product Safety Concerns: Device-related incidents can trigger investigations, corrective measures, and changes to institutional purchasing preferences.

  • Component Supply Concentration: Dependence on specialized materials or limited manufacturing partners creates exposure to external supply disruptions.

  • Procurement Standardization: Hospital purchasing agreements favoring established products can make market entry difficult for smaller or newer suppliers.

Extracorporeal Membrane Oxygenation Cannula Market Segmentation Analysis

The Extracorporeal Membrane Oxygenation Cannula Market can be examined through treatment type, patient characteristics, clinical application, and end-use setting. These dimensions influence cannula design requirements and institutional purchasing decisions. Vascular access configuration determines the relationship between venous drainage, extracorporeal support, and blood return, while patient size affects the available anatomical options. Clinical indications also influence expected support requirements and monitoring practices. The categories are not equally representative of routine ECMO cannula use, and some reflect adjacent extracorporeal applications rather than established ECMO treatment modes.

By Type

Veno-Arterial (VA) ECMO involves venous blood drainage followed by oxygenated blood return to the arterial circulation. This configuration is relevant when patients require circulatory support, frequently in association with severe cardiac dysfunction. Cannula selection must consider arterial access, tissue perfusion requirements, and the potential consequences of peripheral vascular obstruction. These considerations create demand for purpose-designed arterial and venous access devices.

Veno-Venous (VV) ECMO provides extracorporeal respiratory support through venous drainage and venous reinfusion. It represents an important clinical configuration for patients with severe respiratory failure who do not require the circulatory support provided by VA ECMO. Arterio-Venous (AV) configurations are not standard conventional ECMO modes and are more closely associated with selected extracorporeal gas-exchange approaches. Consequently, AV should not be treated as an equivalent established ECMO cannula category when interpreting commercial market segmentation.

By Patient Type

Neonatal ECMO cannulation requires specialized vascular access products suitable for newborn anatomy and the clinical management of critically ill infants. Device selection is influenced by vessel dimensions, congenital conditions, and the need to preserve adequate blood flow. Neonatal applications remain a distinct segment because adult cannulation products cannot simply be scaled down without considering anatomical and physiological differences.

Pediatric patients require additional device configurations spanning a wide range of body sizes and clinical conditions. Congenital cardiac disease and severe respiratory dysfunction contribute to specialized pediatric treatment requirements. The Adult segment encompasses a substantial portion of contemporary ECMO clinical activity, including respiratory and cardiac support in critical care facilities. Adult programs require different cannula configurations according to treatment indication, access strategy, and patient anatomy, making product assortment an important purchasing consideration.

By Application

Respiratory Support represents an important application for ECMO cannulas when severe pulmonary dysfunction prevents adequate oxygenation or carbon dioxide removal despite appropriate conventional treatment. Veno-venous access is commonly associated with this application, and catheter position can influence effective extracorporeal blood flow. Clinical teams consider treatment objectives and anatomical suitability when selecting drainage and reinfusion arrangements.

Cardiac Support primarily involves extracorporeal configurations capable of assisting systemic circulation during severe cardiac dysfunction. The associated cannulation requirements differ from respiratory-only support because arterial reinfusion introduces additional vascular considerations. Extracorporeal Cardiopulmonary Resuscitation (ECPR) is a specialized application involving extracorporeal circulatory support during selected cases of refractory cardiac arrest. ECPR programs place particular emphasis on coordinated emergency workflows, institutional capability, and rapidly accessible equipment. These applications create differentiated requirements for vascular access products rather than a uniform cannula market.

By End Use

Hospitals constitute the principal established end-use environment for ECMO cannulas because extracorporeal life support requires specialized equipment and continuous multidisciplinary care. Tertiary medical centers, cardiothoracic facilities, and advanced intensive care departments provide the clinical infrastructure needed for complex cannulation procedures. Institutional demand is influenced by treatment capability, emergency preparedness, and the availability of appropriate extracorporeal circuits.

Ambulatory Surgical Centers are not typical independent settings for prolonged ECMO treatment because they generally lack the comprehensive intensive care infrastructure needed for such support. Their inclusion should therefore be interpreted cautiously rather than as evidence of substantial established demand. Specialty Clinics may contribute through referral relationships, cardiovascular assessment, or links with hospital-based treatment programs. Actual ECMO cannulation ordinarily remains concentrated in appropriately equipped clinical facilities rather than routine outpatient environments.

Regional Analysis

Regional demand for ECMO cannulas varies according to access to advanced critical care, professional training, medical device regulation, and hospital infrastructure. Established healthcare systems generally provide broader access to specialist extracorporeal treatment programs, while developing networks may rely on referral relationships with experienced centers. Purchasing practices also differ because hospitals operate under distinct public funding, institutional procurement, and device approval frameworks. Reliable comparable regional revenue-share percentages specifically for ECMO cannulas are not consistently available in public evidence, so regional positioning is assessed through documented clinical and institutional characteristics.

North America

North America has an established extracorporeal life support environment supported by specialist hospitals, academic medical centers, and critical care training programs. The United States maintains a structured medical device regulatory system that requires applicable ECMO cannulas to meet established premarket requirements. Hospitals assess devices through clinical purchasing committees, biomedical engineering teams, and procedural specialists. This environment favors suppliers capable of providing product documentation, appropriate technical support, and consistent access to sterile disposables.

Canadian institutions also participate in advanced extracorporeal support care through specialist intensive care and cardiothoracic programs. Provincial healthcare delivery arrangements influence hospital equipment purchasing and the organization of specialized services. Treatment access is concentrated in facilities with the resources needed to support complex extracorporeal procedures.

North American procurement priorities include compatibility with existing clinical systems and dependable availability of approved configurations. Manufacturers must consider distributor performance, hospital inventory procedures, and regulatory obligations when serving institutional customers. The region also provides a significant clinical research environment for investigating cannulation techniques and outcomes. Published studies from specialist centers can influence professional discussion about device selection without automatically demonstrating market-wide adoption or commercial share.

Europe

Europe maintains a diverse ECMO treatment landscape involving university hospitals, cardiothoracic centers, and regional critical care networks. Germany and other established healthcare systems contribute clinical expertise in advanced respiratory and circulatory support. Hospital purchasing requirements are shaped by national healthcare systems, institutional budgets, and the availability of specialist treatment services. Manufacturers must provide suitable product configurations while meeting the regulatory requirements applicable to their devices.

The European Union Medical Device Regulation introduces detailed obligations concerning clinical evaluation, technical documentation, device traceability, and post-market oversight. Mandatory use of designated EUDAMED modules beginning May 2026 further supports structured device registration and certification transparency. These requirements influence manufacturers' regulatory planning and distributor responsibilities.

European healthcare institutions also evaluate the operational implications of sterile disposable products, including packaging integrity and waste management. Product procurement must balance clinical suitability with established hospital purchasing policies and environmental objectives. Engineering collaboration between medical device manufacturers and clinical research groups supports investigation of extracorporeal flow behavior. Such activity contributes technical knowledge relevant to future cannula design and validation.

Asia-Pacific

Asia-Pacific includes healthcare markets with substantial differences in hospital infrastructure, medical device manufacturing capability, and access to specialist extracorporeal care. Japan has an established cardiovascular medical technology industry and specialist institutions experienced in mechanical circulatory support. China combines major hospital systems with domestic medical technology manufacturing and expanding clinical research capabilities. India provides advanced ECMO services through selected tertiary hospitals and specialized critical care institutions.

Australia contributes clinical research and extracorporeal support expertise through major metropolitan hospitals and academic partnerships. Regional professional collaboration supports education in patient selection, treatment coordination, and complex critical care procedures. However, the availability of ECMO services differs considerably between major cities and areas with limited specialist infrastructure.

Manufacturers entering Asia-Pacific markets must address country-specific registration, distribution, and product documentation requirements. Hospital buyers may also prioritize access to application-specific inventory and responsive technical assistance. Local distribution arrangements are important where medical facilities rely on imported specialized consumables. The commercial environment therefore reflects a combination of domestic production, international supply relationships, and the clinical capacity of individual healthcare systems.

Middle East & Africa

The Middle East & Africa region contains established specialist healthcare institutions alongside areas where comprehensive ECMO services remain less accessible. Saudi Arabia and the United Arab Emirates have advanced tertiary hospitals providing specialized cardiac and respiratory critical care. Their institutional requirements create opportunities for suppliers offering approved extracorporeal support products and compatible vascular access devices. Public and private hospital purchasing arrangements influence the selection and availability of specialized medical equipment.

South Africa also has medical centers with extracorporeal support expertise, although access is not uniform across its healthcare system. Regional training initiatives and professional collaboration help support knowledge exchange among participating institutions. The Southwest Asia and Africa chapter of the Extracorporeal Life Support Organization provides a framework for engagement among professionals involved in extracorporeal care.

Procurement challenges include the distribution of specialized consumables across geographically dispersed healthcare facilities. Import processes, storage requirements, and manufacturer support arrangements can influence operational readiness. The expansion of effective referral coordination offers an opportunity to improve appropriate treatment access without assuming that every hospital can independently provide ECMO.

Competitive Landscape

The Extracorporeal Membrane Oxygenation Cannula Market includes manufacturers of dedicated vascular access devices and companies supplying broader extracorporeal support technologies. Medtronic participates through specialized ECMO catheters, including its Bio-Medicus and Crescent product families. Getinge supplies HLS cannulae and related extracorporeal equipment, offering an integrated portfolio for institutions using compatible support systems. LivaNova has documented involvement in extracorporeal treatment technologies and specialized cannulation products, including the ProtekDuo portfolio. Eurosets offers dedicated ECMO and extracorporeal life support cannula configurations, including venous drainage and femoral access products.

Competitive differentiation involves the intended clinical application, product geometry, available configurations, and compatibility with established hospital equipment. Manufacturers must also demonstrate appropriate quality assurance, packaging performance, and regulatory compliance. Institutions may prefer suppliers with dependable distributor networks and access to product-specific clinical education. Technical information concerning blood flow characteristics and device handling supports purchasing assessments.

Some companies associated with cardiopulmonary bypass equipment or broader critical care technologies have adjacent relevance without necessarily competing directly in every dedicated ECMO cannula category. Similarly, historical involvement does not establish current commercial availability. Product-level evidence is therefore more informative than company size when assessing competitive position. Consistent publicly verified company-level market shares specifically for ECMO cannulas are unavailable, preventing reliable numerical rankings.

List of Top Extracorporeal Membrane Oxygenation Cannula Companies

  • Medtronic plc (Ireland)

  • Getinge AB (Sweden)

  • LivaNova PLC (U.K.)

  • Terumo Corporation (Japan)

  • Fresenius Medical Care AG (Germany)

  • Edwards Lifesciences Corporation (U.S.)

  • Abbott Laboratories (U.S.)

  • Nipro Corporation (Japan)

  • Eurosets S.r.l. (Italy)

  • MC3 Cardiopulmonary (U.S.)

  • OriGen Biomedical (U.S.)

  • Andocor (Belgium)

Leading Companies by Market Share

Consistent public company-level market-share percentages specifically covering the global ECMO cannula market are not available. Medtronic and Getinge can nevertheless be identified as important market participants based on their documented dedicated cannula portfolios and established extracorporeal support activities. These positions should not be interpreted as a verified numerical ranking.

Medtronic plc: Medtronic supplies specialized cannulation technologies for ECMO applications, including single-lumen and jugular dual-lumen catheter configurations. Its dedicated product portfolio and associated extracorporeal technologies provide documented competitive relevance.

Getinge AB: Getinge offers arterial and venous HLS cannulae designed for extracorporeal circuit access. Its portfolio includes cannulas with reinforced construction and different surface treatment options for supported applications.

Investment opportunities in the ECMO cannula industry are closely linked to specialized device manufacturing, clinical infrastructure, and the development of dependable supply systems. Precision extrusion, reinforcement processes, controlled assembly, and sterile packaging require manufacturing capabilities appropriate for regulated medical products. Producers seeking to introduce modified cannula designs must allocate resources to verification, validation, and applicable regulatory documentation. These activities create opportunities for specialized manufacturing partners and material suppliers with relevant medical device experience.

Healthcare institutions investing in advanced extracorporeal programs may also require compatible vascular access inventories and technical support services. Capital planning extends beyond equipment acquisition because hospitals must establish treatment pathways, staffing arrangements, and ongoing consumable procurement. Structured supply agreements can support inventory planning where multiple facilities operate within a coordinated healthcare network.

Another investment theme involves improving product distribution reliability and lifecycle management. Appropriate storage infrastructure, batch traceability, and validated packaging processes help manufacturers meet institutional expectations. Digital inventory systems can assist hospitals in monitoring expiration dates and maintaining access to approved product configurations.

Clinical research collaboration also offers opportunities for device companies and academic institutions. Engineering programs examining blood-compatible materials and flow-related performance can generate evidence relevant to future product development. Commercial investment decisions should therefore consider the strength of clinical applications, regulatory feasibility, manufacturing capability, and sustainable institutional demand rather than relying on broader ECMO equipment trends alone.

Product Innovation & Development

Product innovation in ECMO cannulas focuses on blood flow performance, vascular compatibility, mechanical stability, and clinical handling. Cannula engineering requires careful consideration of internal lumen geometry, insertion profile, side-hole configuration, and material properties. Changes to these characteristics can influence pressure losses and blood flow patterns within an extracorporeal circuit. Manufacturers use laboratory testing and engineering analysis to evaluate proposed configurations before clinical application.

The Medtronic Crescent jugular dual-lumen catheter family includes models ranging from 24 Fr to 32 Fr, supporting different anatomical and treatment requirements. Its design incorporates drainage and return pathways within a single catheter structure. Radiopaque markers assist device visualization, while product geometry is intended to support appropriate blood flow. Such features illustrate the importance of combining mechanical engineering with clinical usability.

Material development is another relevant area of product research. Polyurethane structures, reinforcement arrangements, and blood-contacting surface treatments can influence device flexibility, kink resistance, and blood compatibility. Coating selection also requires evaluation of intended use and patient-related contraindications.

Manufacturing improvements include controlled tip formation, reliable component bonding, and dimensional inspection. These processes are important because differences in finished device geometry can affect insertion characteristics and mechanical performance. Future development may benefit from closer integration of computational modeling, laboratory validation, and clinical feedback. However, engineering improvements require appropriate evidence before manufacturers can claim superior clinical outcomes.

Recent Developments (2023–2026)

  • In October 2023, CardiacAssist received U.S. FDA 510(k) clearance for its ProtekDuo Veno-Venous Cannula Sets, establishing regulatory clearance for the specified dual-lumen ECMO cannulation products.

  • In April 2024, Medtronic obtained U.S. FDA 510(k) clearance for its Bio-Medicus Life Support Catheter and Introducer under the single-lumen ECMO cannula classification.

  • In May 2024, Spectrum Medical S.R.L. received U.S. FDA 510(k) clearance for its Quantum Perfusion Dual Lumen Cannula 31F-V1, supporting regulatory access for the specified extracorporeal cannulation device.

  • In September 2024, Getinge announced the conditional reinstatement of its CE certificate for HLS and PLS extracorporeal life support consumables following assessment of its revised packaging solution.

  • In January 2026, Medtronic received another U.S. FDA 510(k) substantial equivalence decision for its Bio-Medicus Life Support Catheter and Introducer under the single-lumen ECMO cannula device classification.

Scope of the Extracorporeal Membrane Oxygenation Cannula Market Report

The Extracorporeal Membrane Oxygenation Cannula Market report examines the characteristics of specialized vascular access products used in extracorporeal respiratory and circulatory support. Its segmentation framework covers Veno-Arterial, Veno-Venous, and Arterio-Venous classifications while distinguishing conventional ECMO applications from adjacent extracorporeal approaches. Patient analysis includes neonatal, pediatric, and adult requirements, with attention to anatomical differences and clinical treatment settings. Application coverage addresses respiratory support, cardiac support, and extracorporeal cardiopulmonary resuscitation.

The report evaluates hospitals, ambulatory surgical centers, and specialty clinics according to their documented or potential relationships with ECMO cannula utilization. Geographic coverage includes North America, Europe, Asia-Pacific, and the Middle East & Africa, emphasizing clinical infrastructure, regulation, procurement, and regional access conditions. Market dynamics address the factors affecting device adoption, commercial opportunities, operational restraints, and manufacturing challenges.

SWOT analysis examines structural strengths, weaknesses, opportunities, and threats associated with this specialized medical device category. Competitive coverage considers manufacturer portfolios, technical differentiation, regulatory position, and verified product relevance. Investment and innovation analysis assesses manufacturing capabilities, product engineering, and institutional purchasing requirements. Recent developments cover documented manufacturer activities and regulatory decisions relevant to extracorporeal cannulation technologies.

Extracorporeal Membrane Oxygenation Cannula Market Report Scope & Segmentation

AttributesDetails
Market Size (Current)Current market valuationUS$ 38.7 Million in 2026
Market Size (Forecast)Projected market valuationUS$ 55.56 Million in 2035
Growth RateCompound Annual Growth RateCAGR of 4.1% from 2026 to 2035
Forecast PeriodAnalysis timeline2026 – 2035
Base YearReference year for analysis2025
Historical Data AvailablePast market data availabilityYes
Regional ScopeGeographical coverageGlobal
Segments CoveredMarket segments analyzed

By Type

  • Veno-Arterial (VA)

  • Veno-Venous (VV)

  • Arterio-Venous (AV)

By Patient Type

  • Neonates

  • Pediatric

  • Adult

By Application

  • Respiratory Support

  • Cardiac Support

  • Extracorporeal Cardiopulmonary Resuscitation (ECPR)

By End Use

  • Hospitals

  • Ambulatory Surgical Centers

  • Specialty Clinics

Key Market Players

Leading companies covered in this report

  • Medtronic plc (Ireland)
  • Getinge AB (Sweden)
  • LivaNova PLC (U.K.)
  • Terumo Corporation (Japan)
  • Fresenius Medical Care AG (Germany)
  • Edwards Lifesciences Corporation (U.S.)
  • Abbott Laboratories (U.S.)
  • Nipro Corporation (Japan)
  • Eurosets S.r.l. (Italy)
  • MC3 Cardiopulmonary (U.S.)
  • OriGen Biomedical (U.S.)
  • Andocor (Belgium)

Frequently Asked Questions

Common questions about this report

The study period covers historical insights and forecast projections for the period 2026-2035.

About the Author

Market research expert with years of industry experience

Dipali Bhingare

Dipali Bhingare

Market Research Director

Dipali Bhingare serves as the Market Research Director at Econ Market Research. With a focus on translating complex global economic shifts into actionable business intelligence, she oversees the strategic direction of comprehensive market studies. Her work empowers organizations to navigate volatile industries through data-driven forecasting and deep-dive competitive analysis.

more about Dipali

Related Reports

Explore more market insights from the same category

Blood Bank Serology MarketCannula MarketLiposuction Surgery Devices MarketOvulation Testing Kits Market
Browse All Reports

Our Clients

3M logo
Accenture logo
Apyx Medical logo
Atlas Copco logo
GE General Electric logo
IBM logo
Johnson and Johnson logo
LEK Consulting logo
Leschaco logo
Medtronic logo
TruGolf logo
Wieth Medical logo
3M logo
Accenture logo
Apyx Medical logo
Atlas Copco logo
GE General Electric logo
IBM logo
Johnson and Johnson logo
LEK Consulting logo
Leschaco logo
Medtronic logo
TruGolf logo
Wieth Medical logo